Diabetes News

ORLANDO — An inhaled insulin was noninferior to usual care for change in HbA1c and continuous glucose monitoring metrics among adults with type 1 diabetes, according to data from the INHALE-3 trial.

ORLANDO — Race-conscious medicine can help to identify those at higher risk for prediabetes and diabetes; however, this method can exacerbate racism and impede health equity, according to two speakers.

ORLANDO — The GIP/GLP-1 dual agonist tirzepatide reduced symptoms of obstructive sleep apnea and improved multiple cardiometabolic markers for adults with obesity and obstructive sleep apnea, according to data from the SURMOUNT-OSA trial.

ORLANDO — A tubeless automated insulin delivery system improved multiple glycemic outcomes among a large group of adults with type 2 diabetes, according to data presented at the American Diabetes Association Scientific Sessions.

ORLANDO — The U.S. health care community must focus on getting diabetes therapies, technology and tools into the hands of all people with diabetes, especially those with low incomes and living in rural communities, according to a speaker.

Fidelma Dunne, MD, PhD, FRCP, FRCPI, describes herself as a wife, mother, grandmother, sister and daughter who draws satisfaction from her family and from her career in endocrinology.

PHILADELPHIA — In the cardiovascular outcomes analysis of the GRADE trial, liraglutide was linked to lower risk for certain CV outcomes compared with other glucose-lowering therapies, researchers reported.

The past 10 years have seen rapid growth in research on how endocrine-disrupting chemicals affect humans.

Presentations on the SURMOUNT-OSA, FLOW, INHALE-3 and TIGHT trials are among the many highlights at the American Diabetes Association’s 84th Scientific Sessions.

Hypertension expert and longtime editorial board member for Healio | Cardiology and Healio | Endocrinology George L. Bakris, MD, died June 15, 2024, at the age of 72.